Durvalumab: A Review in Extensive-Stage SCLC
Author:
Open Access
- 3 November 2021
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 16 (6) , 857-864
Abstract
Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the pivotal phase III CASPIAN trial in previously untreated adults with ES-SCLC, the addition of durvalumab to chemotherapy for up to 4 cycles followed by maintenance durvalumab was associated with a significantly longer overall survival and a favourable hazard ratio for progression-free survival compared with chemotherapy alone for up to 6 cycles. A higher proportion of patients in the durvalumab plus chemotherapy group had an objective response compared with the chemotherapy alone group. The efficacy of durvalumab was also sustained with longer follow-up. Durvalumab in combination with etoposide and either carboplatin or cisplatin had a manageable tolerability profile in patients with ES-SCLC. Given the available evidence, durvalumab in combination with etoposide and either carboplatin or cisplatin represents a valuable treatment option for the first-line treatment of patients with ES-SCLC, and is an accepted standard of care option in this setting.Keywords
This publication has 14 references indexed in Scilit:
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2021
- Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III studyLung Cancer, 2020
- LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIANAnnals of Oncology, 2019
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Current Diagnosis and Management of Small-Cell Lung CancerMayo Clinic Proceedings, 2019
- What's New in SCLC? A ReviewNeoplasia, 2017
- Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and agesScientific Reports, 2017
- PD-L1 expression in human cancers and its association with clinical outcomesOncoTargets and Therapy, 2016
- Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians GuidelineJournal of Clinical Oncology, 2015
- Treatment of Small Cell Lung CancerChest, 2013